H. Schulz

27.7k total citations · 2 hit papers
118 papers, 3.2k citations indexed

About

H. Schulz is a scholar working on Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, H. Schulz has authored 118 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pathology and Forensic Medicine, 31 papers in Pulmonary and Respiratory Medicine and 30 papers in Genetics. Recurrent topics in H. Schulz's work include Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (20 papers) and CNS Lymphoma Diagnosis and Treatment (15 papers). H. Schulz is often cited by papers focused on Lymphoma Diagnosis and Treatment (32 papers), Chronic Lymphocytic Leukemia Research (20 papers) and CNS Lymphoma Diagnosis and Treatment (15 papers). H. Schulz collaborates with scholars based in Germany, United States and United Kingdom. H. Schulz's co-authors include Andreas Engert, Volker Diehl, Oliver Manzke, U. Winkler, Mark A. Jensen, Hendrik Pels, Julia Bohlius, Marcel Reiser, A. G. Buckley and J. M. Butterworth and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

H. Schulz

106 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

1999 516 citations U. Winkler, Oliver Manzke et al. profile →
Rivet user manual

2013 285 citations H. Schulz et al. profile →

Peers

Countries citing papers authored by H. Schulz

Since Specialization

Citations

This map shows the geographic impact of H. Schulz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Schulz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Schulz more than expected).

Fields of papers citing papers by H. Schulz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Schulz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Schulz. The network helps show where H. Schulz may publish in the future.

Co-authorship network of co-authors of H. Schulz

This figure shows the co-authorship network connecting the top 25 collaborators of H. Schulz. A scholar is included among the top collaborators of H. Schulz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Schulz. H. Schulz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Head‐to‐head comparison of palbociclib and ribociclib in first‐line treatment of HR‐positive/HER2‐negative metastatic breast cancer with real‐world data from the OPAL registry 2024 ·International Journal of Cancer ·Marc Thill, (unknown), Anja Welt, Arnd Nusch, Matthias Zaiß, (unknown), (unknown), Kai G. Ringwald, (unknown), (unknown), (unknown), Martina Jänicke, H. Schulz, Volker Hagen, (unknown), Elmar Stickeler, Nadia Harbeck, Achim Wöckel, Thomas Decker	5
2	Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study 2024 ·European Journal Of Haematology ·(unknown), Steffen Dörfel, H. Schulz, Rudolf Schlag, (unknown), (unknown), Manfred Welslau	0
3	Subclinical impairment of the left atrium is associated with MRI-based lung volume but not with parameters from pulmonary function testing 2024 ·Scientific Reports ·(unknown), Roberto Lorbeer, Blerim Mujaj, Bernard E. Bulwer, Susanne Rospleszcz, (unknown), H. Schulz, Stefan Karrasch, Annette Peters, Christopher L. Schlett, Fabian Bamberg, (unknown)	0
4	Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report 2023 ·JCO Precision Oncology ·(unknown), Jana Fassunke, Michael Püsken, (unknown), Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogová, Richard Riedel, (unknown), (unknown), Matthias Scheffler, H. Schulz, (unknown), Thomas Zander, Sabine Merkelbach‐Bruse, Peter Schirmacher, Reinhard Büttner, Jürgen Wolf, Sebastian Michels	2
5	232P Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL 2022 ·Annals of Oncology ·Norbert Marschner, Nadia Harbeck, (unknown), Elmar Stickeler, (unknown), Arnd Nusch, (unknown), H. Schulz, (unknown), (unknown), Martina Jänicke, (unknown), Achim Wöckel, Anja Welt, (unknown)	3
6	Brain Metastases in Elderly Patients—The Role of Surgery in the Context of Systemic Treatment 2021 ·Brain Sciences ·Martin Proescholdt, Stephanie T. Jünger, Petra Schödel, Karl-Michael Schebesch, Christian Doenitz, Tobias Pukrop, Julius Höhne, Nils Ole Schmidt, Martin Köcher, H. Schulz, Maximilian I. Ruge, (unknown), Roland Goldbrunner, Stefan Grau	11
7	Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score 2019 ·Cancer Medicine ·Maria Rita Gaiser, Sylvie Lorenzen, Kirsten Merx, Jörg Trojan, Janja Ocvirk, Thomas J. Ettrich, Salah‐Eddin Al‐Batran, H. Schulz, Nils Homann, (unknown), Michael Schatz, Melanie Kripp, Nadine Schulte, S. Heeger, Soetkin Vlassak, Winfried Koch, Ralf‐Dieter Hofheinz	4
8	Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study 2019 ·Anticancer Research ·Wolfgang Schultze‐Seemann, H. Schulz, (unknown), (unknown)	5
9	Three-flavored nonresonant leptogenesis at intermediate scales 2018 ·Physical review. D ·K. Moffat, Silvia Pascoli, (unknown), H. Schulz, Jessica Turner	40
10	P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy 2015 ·Annals of Oncology ·Carsten Bokemeyer, H. Schulz, Jan Janßen, Urban Scheuring, (unknown)	0
11	The Relationship Between Individual Resource Realization and Sociodemographic and Clinical Characteristics in Mentally Ill Patients 2012 ·Journal of Clinical Psychology ·Maria Hausberg, H. Schulz, Sylke Andreas	0
12	HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL SUPPORT IN FIRST LINE TREATMENT OF AGGRESSIVE NON HODGKIN LYMPHOMA: RESULTS OF AN INDIVIDUAL PATIENT DATA META-ANALYSIS 2009 ·IRIS Research product catalog (Sapienza University of Rome) ·Corinne Brillant, Guido Schwarzer, Julia Bohlius, (unknown), Sven Trelle, Corinne Haïoun, André De Souza, Christian Gisselbrecht, Tanin Intragumtornchai, Ulrich Kaiser, (unknown), Maurizio Martelli, Nöel Milpied, (unknown), Umberto Vitolo, Andreas Engert, H. Schulz	1
13	Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review 2009 ·Haematologica ·Christine Herbst, (unknown), Corinne Brillant, Julia Bohlius, Nicole Skoetz, H. Schulz, Ina Monsef, Lena Specht, Andreas Engert	67
14	Ultrafine Particles: Geiser et al. Respond 2006 ·Environmental Health Perspectives ·Marianne Geiser, Barbara Rothen‐Rutishauser, Nadine Kapp, Peter Gehr, Samuel Schürch, Wolfgang G. Kreyling, H. Schulz, Manuela Semmler, J. Heyder, Vinzenz Im Hof	2
15	Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia 2002 ·Annals of Hematology ·(unknown), Marcel Reiser, Stefan Barth, Peter Borchmann, H. Schulz, (unknown), (unknown), J. Wessels, (unknown), Volker Diehl, Andreas Engert	15
16	Intraventricular and Intravenous Treatment of a Patient with Refractory Primary CNS Lymphoma using Rituximab 2002 ·Journal of Neuro-Oncology ·Hendrik Pels, H. Schulz, Oliver Manzke, (unknown), Aron D. Thall, Andreas Engert	54
17	The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells 2002 ·BMC Cell Biology ·(unknown), H. Schulz, Dieter A Wolf	61
18	Current strategies of antibody‐based treatment in Hodgkin's disease 2002 ·Annals of Oncology ·R. Schnell, Peter Borchmann, H. Schulz, Andreas Engert	22
19	A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia 2000 ·Leukemia ·(unknown), Andreas Engert, (unknown), Timo Schinköthe, F. Oberhäuser, H. Schulz, Volker Diehl, Stefan Barth	37
20	The Monoclonal Antibodies Campath-1H and Rituximab in theTherapy of Chronic Lymphocytic Leukemia 2000 ·Oncology Research and Treatment ·H. Schulz, U. Winkler, Jan Oliver Staak, Andreas Engert	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact